SHEN26

CAS No. 2647441-36-7

SHEN26( —— )

Catalog No. M28490 CAS No. 2647441-36-7

SHEN26 has antiviral activity and can be used in research on the treatment of viral infections.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 222 Get Quote
10MG 357 Get Quote
25MG 597 Get Quote
50MG 851 Get Quote
100MG 1152 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    SHEN26
  • Note
    Research use only, not for human use.
  • Brief Description
    SHEN26 has antiviral activity and can be used in research on the treatment of viral infections.
  • Description
    SHEN26 has antiviral activity and can be used in research on the treatment of viral infections.
  • In Vitro
    Obeldesivir (0.001-100 μM; 48 h; Vero E6 cells) inhibits the replication of authentic SARS-CoV-2 and its variants of concern. Obeldesivir has an overall >4-fold and >12-fold potency improvement in inhibiting the replication of Delta and Omicron variants, with EC50 values of 0.349 μM and 0.106 μM, respectively.
  • In Vivo
    Obeldesivir (5-25 mg/kg; p.o. and i.v.; Sprague Dawley rats) has favorable pharmacokinetic profiles in rats with high oral bioavailability (F %) of 81.5% and maximum blood concentration (Cmax) of 8.2 μM.Obeldesivir (250-500 mg/kg; p.o.; daily, for 4 days; hACE2 knock-in and Ad5-hACE2 mice) has antiviral activity and inhibits SARS-CoV-2 replication in mouse models.Obeldesivir (100-250 mg/kg; p.o.; daily, for 10 days) reduces lung damage and protects K18-hACE2 mice.Obeldesivir (10-150 mg/kg; p.o.; daily, for 3 days) reduces virus titers and lung damage caused by Delta variant infection in K18-hACE2 mice. Animal Model:hACE2 knock-in and Ad5-hACE2 mice Dosage:250 and 500 mg/kg Administration:Oral administration; daily, for 4 days Result:Inhibited gRNA and sgRNA, which is Biomarkers of coronavirus replication. Reduced the viral load and pathological damage of the lung.Animal Model:K18-hACE2 mice Dosage:100 and 250 mg/kg Administration:Oral administration; daily, for 10 days Result:Reduced viral RNA and increased the survival rate of mice. Reduced evidence of lung pathology and the production of inflammatory cytokines and chemokines in the lung tissues.Animal Model:K18-hACE2 mice Dosage:10, 30, 80 and 150 mg/kg Administration:Oral administration; daily, for 3 days Result:Reduced viral load in a dose-dependent manner and alleviated the symptoms in the lung.
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    Antiviral
  • Recptor
    mTOR| PI3Kα/PI3Kγ
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2647441-36-7
  • Formula Weight
    361.35
  • Molecular Formula
    C16H19N5O5
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (691.85 mM)
  • SMILES
    N#C[C@@]1(C2=CC=C3N2N=CN=C3N)O[C@H](COC(C(C)C)=O)[C@@H](O)[C@H]1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • SARS-CoV-2 nsp13-IN-...

    SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent inhibitor of nsp13 (non-structural protein 13), selectively inhibiting nsp13 ssDNA+ATPase with an IC50 of 6 μM, but not ssDNA-ATPase, and can be used to study COVID-19.

  • (R,1R)-Tenofovir ami...

    (R,1R)-Tenofovir amibufenamide ((R,1R)-HS-10234) is an orally administered Tenofovir prodrug with antiviral activity. Tenofovir is a nucleotide reverse transcriptase inhibitor.

  • ITMN4077

    ITMN4077 has antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication with an EC50 of 2.131μM.